JAMA 302:883–889CrossRef 47. Kruger MC, Schollum LM, Kuhn-Sherlock B, Hestiantoro
A, Wijanto P, Li-Yu J, Agdeppa I, Todd JM, www.selleckchem.com/products/mek162.html Eastell R (2010) The effect 4EGI-1 nmr of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone 46:759–767PubMedCrossRef 48. Prince RL, Devine A, Dhaliwal SS, Dick IM (2006) Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 166:869–875PubMedCrossRef 49. Commission E (2002) Price differences for supermarket goods in Europe. Internal working document of the Internal Market Directorate General. European Commission, Brussels 50. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium SRT2104 mw or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666PubMedCrossRef 51. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, Kanis JA, Orav EJ, Staehelin HB, Kiel DP, Burckhardt P, Henschkowski J, Spiegelman D, Li R, Wong JB, Feskanich D, Willett WC (2011) Milk intake and risk of hip fracture in men and women: a meta-analysis of prospective
cohort studies. J Bone Miner Res 26:833–839PubMedCrossRef 52. Warensjo E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, Michaelsson K (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473PubMedCrossRef 53. Avenell A, Gillespie WJ, Gillespie LD, O’Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2):CD000227 54. Dawson-Hughes B, Harris SS (2002) Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. Am J Clin Nutr 75:773–779PubMed 55. Walker-Bone K, Walter G, Cooper C (2002) Recent developments
in the epidemiology of osteoporosis. Curr Opin Rheumatol 14:411–415PubMedCrossRef 56. Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related Methane monooxygenase fractures in Sweden. Osteoporos Int 17:637–650PubMedCrossRef 57. Borgström F, Johnell O, Kanis JA, Jönsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471PubMedCrossRef 58. Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA (2008) Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK: results based on the Women’s Health Initiative randomised controlled trial. Bone 42:294–306PubMedCrossRef 59.